Long‐term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide‐based reinduction and maintenance regimens: A 15‐year prospective study. Issue 11 (26th March 2018)

• Record Type: Journal Article
• Authors: Gill, Harinder; Yim, Rita; Lee, Harold K. K.; Mak, Vivien; Lin, Shek‐Ying; Kho, Bonnie; Yip, Sze‐Fai; Lau, June S. M.; Li, Wah; Ip, Ho‐Wan; Hwang, Yu‐Yan; Chan, Thomas S. Y.; Tse, Eric; Au, Wing‐Yan; Kumana, Cyrus R.; Kwong, Yok‐Lam
• Is Part Of: Cancer. Volume 124:Issue 11(2018)
• Page Start: 2316
• Page End: 2326
• Publication Date: 2018-03-26
• Subjects: acute promyelocytic leukemia -- oral arsenic trioxide maintenance -- relapse -- second complete remission; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.31327
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : BACKGROUND: For patients who have acute promyelocytic leukemia (APL) in second complete remission (CR2), optimal postremission strategies remain undefined. METHODS: The role of an oral arsenic trioxide (As2 O3 )‐based regimen in the management of patients who had APL in CR2 was examined. RESULTS: Seventy‐three patients with APL in first relapse (R1) were studied. Oral As2 O3 ‐based reinduction resulted uniformly in CR2, irrespective of previous As2 O3 exposure. All patients received oral As2 O3 ‐based maintenance in CR2. At a median follow‐up of 94 months (range, 9‐205 months), 43 patients (58.9%) were still in CR2, and 49 (67.1%) had finished the planned 2‐year CR2 maintenance with all‐trans retinoic acid, oral As2 O3, and ascorbic acid. Reinduction and maintenance treatments were well tolerated. Grade 1 and 2 headache occurred in 20 patients (27.4%). Hepatotoxicity, all in the form of transaminitis, occurred in 35 patients (47.9%; grade 1 and 2, n = 26; grade 3 and 4, n = 9). Three patients had self‐limiting QTc prolongation. The 10‐year leukemia‐free survival rate was 56.8%. Thirty patients developed R2. Oral As2 O3 ‐based reinduction led to CR3 in 27 patients (90%). Post‐CR3 strategies included autologous hematopoietic stem cell transplantation and oral As2 O3 maintenance. At a post‐CR3 follow‐up of 30 months (range, 3‐166 months), 11 patients were still in CR3. The 5‐year and 10‐year overall survival rates in the R1 cohort were 79.5% and 67.3%, respectively. Prior receipt of oral As2 O3 maintenance in CR1 was the only risk factor for inferior leukemia‐free survival. Central nervous system involvement occurred in 15 patients, including 5 who remained alive. Relapse during oral As2 O3 therapy was the only significant risk factor for central nervous system involvement. CONCLUSIONS: For patients with relapsed APL, As2 O3 remained effective despite repeated As2 O3 exposures. Oral As2 O3 maintenance was an effective postremission strategy for CR2. Cancer 2018;124:2316‐26 . © 2018 American Cancer Society . Abstract : Oral arsenic trioxide‐based regimens are effective in inducing and maintaining second complete remission in patients who have acute promyelocytic leukemia in first relapse, irrespective of previous exposure to arsenic trioxide. In more advanced relapses, arsenic trioxide remains effective, although the efficacy progressively decreases, and central nervous system involvement becomes more frequent.